Press release -

Nyemissionerna i Enzymatica har registrerats

Nyemissionerna i Enzymatica AB (publ) (”Enzymatica”) har registrerats av Bolagsverket den 26 april 2014. I samband med att emissionerna har registrerats av Bolagsverket kommer betalda tecknade aktier (BTA), som handlas under kortnamnen ENZY BTA och ENZY BTA 2, att avregistreras och ersättas av nya aktier. Sista dag för handel med ENZY BTA och ENZY BTA 2 på AktieTorget är den 30 april 2014. De nya aktierna beräknas vara levererade till respektive tecknares VP-konto eller depå torsdagen den 8 maj 2014.

För mer information om Enzymatica, kontakta:
Michael Edelborg Christensen, VD Enzymatica AB (publ), 0768-14 41 66, michael.christensen@enzymatica.se


Topics

  • Economy, Finance

Categories

  • enzymatica
  • enzy bta
  • enzy bta 2
  • bta
  • bta 2

About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.

About Enzymatica online
Enzymatica’s press room »
Enzymatica’s website »
Enzymatica on LinkedIn »
Enzymatica on twitter »
For Investors »
For Investors »
ColdZyme website »
ColdZyme on facebook »


Contacts

Fredrik Lindberg

Press contact CEO +46 (0)708-86 53 70

Related media

Nyemissionerna i Enzymatica har registrerats
  • Nyemissionerna i Enzymatica har registrerats
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
  • File format: .pdf
Download

Related content

Enzymaticas rights issue oversubscribed

THIS PRESS RELEASE IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION SHOULD NOT BE COMPATIBLE WITH APPLICABLE REGULATIONS
Enzymatica AB (publ) ("Enzymatica" or the "Company") has completed the rights issue of shares as decided by the Board on 16 February